Salubris Biotherapeutics, Inc.

About Salubris Biotherapeutics, Inc.

Salubris Biotherapeutics, Inc. (SalubrisBio) is a clinical-stage biotechnology company focused on discovering and developing innovative antibody and protein-based therapeutics to address significant unmet medical needs, aiming to improve disease burden and quality of life for patients.

Products & Services

Cardiovascular Therapeutics:Potential treatments targeting cardiovascular disease, one of the leading causes of death worldwide.

Specialties

Antibody and Protein-Based Therapeutics Cardiovascular Disease Treatments Oncology Treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing T: - FT: Financing	A: 35000000 MR: - FA: $35 million FAN: 35000000	D: 2024-04-22 FD: 2024-04-22	1 investors
2	RT: Financing T: - FT: Financing	A: 35000000 MR: - FA: $35 million FAN: 35000000	D: 2023-03-28 FD: 2023-03-28	1 investors

Financing Latest

2024-04-22

$35.0M

1 investor (Pro only)

Financing 2023-03-28

$35.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sam Murphy

Chief Executive Officer

S

Shalabh Singhal

MD, Chief Medical Officer

J

Jijun Dong

Chief Scientific Officer

S

Stephen DiPalma

Interim Chief Financial Officer

A

Amanda McEwen

SVP of Clinical Development and JK07 Program Lead

J

Jinhua Feng

VP, Head of CMC

View 5 more team members with Pro

Unlock Full Team Directory

Recent News